Search results for "aberrations"

showing 10 items of 192 documents

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

2021

PETHEMA/GEM Cooperative Group.

OncologyAdultBoron CompoundsMalemedicine.medical_specialtyNeoplasm ResidualPhysics::Instrumentation and DetectorsClinical Trials and ObservationsImmunologyPatient subgroupsGlycineDrug resistanceBiochemistryDexamethasoneBortezomibhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmHumansProgression-free survivalTreatment resistanceLenalidomideComplete responseMultiple myelomaAgedChromosome AberrationsLymphoid Neoplasiabusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseFlow CytometryProgression-Free Survivalbody regionsClinical trialTreatment OutcomeDrug Resistance NeoplasmFemalebusinessMultiple Myeloma
researchProduct

Frequent chromosomal gains in recurrent juvenile nasopharyngeal angiofibroma.

2007

Juvenile nasopharyngeal angiofibroma (JNA) is a rare benign tumor, mostly affecting adolescent males. Some patients develop recurrences after surgery independently of completeness of removal. Only very limited data concerning underlying chromosomal changes are available. We therefore analyzed samples of 22 JNAs, including six recurrences, with comparative genomic hybridization (CGH). Additionally, quantitative image cytometry was used for measurement of DNA aneuploidy in representative samples. Of the 13 primary JNAs without later recurrence, DNA gains were identified on autosomes in only two samples. Four patients with one or two recurrences were included in the study; for one of these, no…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentJuvenile nasopharyngeal angiofibromaBiologyBioinformaticsAngiofibromaBenign tumorInternal medicineGeneticsmedicineHumansChildMolecular BiologyGeneChromosome AberrationsAutosomeNucleic Acid HybridizationNasopharyngeal NeoplasmsGenomicsDna amplificationmedicine.diseasePrimary tumorChromosome 4Neoplasm Recurrence LocalComparative genomic hybridizationCancer genetics and cytogenetics
researchProduct

Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of th…

2000

We determined prospectively the incidence of chromosomal abnormalities in patients with high-risk breast cancer (HRBC) after high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT), and correlated the cytogenetic abnormalities with the development of post-transplant myelodysplastic syndrome or acute myeloid leukemia (MDS/AML). From 1990 to 1999, 229 women with HRBC underwent ASCT. Cytogenetic analysis of bone marrow (BM) cells was performed 12–59 months after ASCT in 60 consecutive women uniformly treated with six courses of FAC/FEC followed by HDCT and ASCT. With a median follow-up of 36 months after ASCT, there were no cases of MDS/AML among the 229 patients. In the …

OncologyAdultmedicine.medical_specialtyPathologyPopulationAneuploidyBreast NeoplasmsTransplantation AutologousBreast cancerAutologous stem-cell transplantationBone MarrowPredictive Value of Testshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAdjuvant therapyMedicineHumanseducationCyclophosphamideEpirubicinNeoplasm StagingChromosome AberrationsTransplantationeducation.field_of_studyLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyTransplantationPostmenopausemedicine.anatomical_structurePremenopauseChemotherapy AdjuvantDoxorubicinMyelodysplastic SyndromesFemaleBone marrowFluorouracilbusinessBone marrow transplantation
researchProduct

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Gr…

2020

Purpose: For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome. Patients and methods: Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIO…

OncologyCancer Researchmedicine.medical_specialtyGenomicsNeuroblastomaCogInternal medicineNeuroblastomaHumansMedicineProgression-free survivalSurvival rateNeoplasm StagingChromosome AberrationsClinical Trials as TopicN-Myc Proto-Oncogene ProteinValidation groupbusiness.industryChromosomes Human Pair 11Age FactorsGene AmplificationInfantORIGINAL REPORTSGenomicsPrognosismedicine.diseaseDiploidyProgression-Free SurvivalDoenças GenéticasSurvival RateOncologyPediatric OncologyChromosomes Human Pair 1Mycn amplificationNeoplasm stagingbusinessJournal of Clinical Oncology
researchProduct

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

2012

Background: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. Methods: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. Results: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental a…

OncologyCancer Researchmedicine.medical_specialtyPathologyBiologyLoss of heterozygosityneuroblastomaNeuroblastomaInternal medicineINRGmedicineHumansClinical significancegenomic profileSurvival analysisRetrospective StudiesChromosome AberrationsOncogene ProteinsN-Myc Proto-Oncogene ProteinUnivariate analysisgenetic alterationsChromosomes Human Pair 11InfantNuclear ProteinsChromosomeGenetics and GenomicsPrognosismedicine.diseaseSurvival AnalysisOncologyGenetic markerGenomic ProfileChromosomes Human Pair 17British Journal of Cancer
researchProduct

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblasto…

2011

BACKGROUND: In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse. METHODS: In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enrolled in the prospective European INES trials. RESULTS: Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients wh…

OncologyCancer Researchmedicine.medical_specialtyPathologyChromosomal AlterationsN-Myc Proto-Oncogene Proteinsegmental chromosome alterationsneuroblastomaNeuroblastomaRecurrenceInternal medicineNeuroblastomamedicineHumansProspective StudiesStage (cooking)Relapse riskProspective cohort studygenomic profileSurvival analysisChromosome AberrationsOncogene ProteinsN-Myc Proto-Oncogene Proteininfantsbusiness.industryInfantNuclear ProteinsGenetics and GenomicsPrognosismedicine.diseaseSurvival AnalysisDoenças GenéticasOncologySegmental Chromosome AlterationsHigh RiskGenomic ProfilebusinessBritish Journal of Cancer
researchProduct

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

2016

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab (Cycle 1; 300 mg) plus FC every 4 weeks for six cycles. Median C(max) and C(trough) values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher C(max) and C(trough) values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas …

OncologyMaleCancer ResearchLymphomaDrug ResistanceMedizinKaplan-Meier EstimatePharmacologychemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocols80 and overChronicNeoplasm MetastasisLenalidomideCancerAged 80 and overUnivariate analysisLeukemiaRemission InductionAntibodies MonoclonalHematologyphase IIMiddle AgedLymphocyticThalidomideFludarabineClinical trialTreatment OutcomeOncologyTolerability6.1 Pharmaceuticals030220 oncology & carcinogenesisRetreatmentMathematikRituximabFemalePatient SafetyRefractory Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemiamedicine.drugAdultmedicine.medical_specialtyCyclophosphamidelenalidomideClinical Trials and Supportive ActivitiesClinical SciencesImmunologyCmaxAntineoplastic AgentsNeutropeniaOfatumumabAntibodies Monoclonal HumanizedDrug Administration ScheduleArticle03 medical and health sciencesRare DiseasesClinical ResearchChemoimmunotherapyInternal medicinemedicineImmunologic FactorsAnimalsHumansIn patientAdverse effectLenalidomideAgedNeoplasm StagingChromosome Aberrationsbusiness.industryB-CellEvaluation of treatments and therapeutic interventionsmedicine.diseaseHaresLeukemia Lymphocytic Chronic B-CellDiscontinuationClinical trialchemistryDrug Resistance NeoplasmNeoplasmbusinessCLL030215 immunology
researchProduct

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.

2007

BACKGROUND. Clonal cytogenetic abnormalities (CCA) were detected in Philadelphia chromosome (Ph)-negative cells in some patients with chronic myeloid leukemia (CML) who attained a cytogenetic response to imatinib mesylate. In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells. METHODS. The authors compared the pretherapeutic risk factors (Kruskall-Wallis test), exposure to cytotoxic drugs (chi-square test), and overall and progression-free survival (Kaplan-Meyer and logistic regression analysis, respectively) of 515 patients with mostly chronic-…

OncologyMaleCancer ResearchMyeloidKaplan-Meier EstimatePiperazineshemic and lymphatic diseasesTreatment FailureAged 80 and overMyeloid leukemiaMiddle AgedPrognosisLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyBenzamidesCytogenetic AnalysisImatinib MesylateFemalemedicine.drugAdultmedicine.medical_specialtyNeutropeniaAntineoplastic AgentsPhiladelphia chromosomeDisease-Free SurvivalLeukemia Myeloid Chronic Atypical BCR-ABL Negativechronic myeloid leukemiaInternal medicineparasitic diseasesmedicineHumansAgedChromosome AberrationsChi-Square Distributionbusiness.industryMyelodysplastic syndromesCancerInterferon-alphaImatinibmedicine.diseaseThrombocytopeniaImatinib mesylateLogistic ModelsPyrimidinesMyelodysplastic SyndromesChronic DiseaseCancer researchbusinessFollow-Up StudiesCancer
researchProduct

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy includi…

2015

Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.

OncologyMalemedicine.medical_treatmentarray-based comparative genomic hybridization (aCGH)Intensive chemotherapyKaplan-Meier EstimateBioinformatics0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy ProtocolsYoung adultComparative Genomic HybridizationGenomeArray-based comparative genomic hybridizationBurkitt lymphomaHigh-Throughput Nucleotide SequencingHematologyMiddle AgedPrognosisBurkitt Lymphomahumanities3. Good healthTreatment Outcome030220 oncology & carcinogenesisoutcomeRituximabFemaleRituximabmedicine.drugAdultmedicine.medical_specialtyAdolescenteducationBiologyNext-generation sequencing outcome03 medical and health sciencesYoung AdultInternal medicinemedicineHumansIn patientAgedChromosome AberrationsChemotherapymedicine.diseaseGNA13Lymphomastomatognathic diseasesnext-generation sequencing030215 immunologyComparative genomic hybridization
researchProduct

Effect of even and odd-order aberrations on the accommodation response

2017

Aim To investigate the potential effect that odd and even-order monochromatic aberrations may have on the accommodation response of the human eye. Methods Eight healthy subjects with astigmatism below 1 D, best corrected visual acuity 20/20 or better and normal findings in an ophthalmic examination were enrolled. An adaptive optics system was used in order to measure the accommodation response of the subjects' eyes under different conditions: with the natural aberrations being present, and with the odd and even-order aberrations being corrected. Three measurements of accommodation response were monocularly acquired at accommodation demands ranging from 0 to 4 D (0.5 D step). Results The acc…

Ophthalmic examinationAstigmatism050105 experimental psychologyadaptive optics03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyClinical Researchmonochromatic aberrationsMedicine0501 psychology and cognitive sciences10. No inequalityAdaptive opticsaccommodation responseBest corrected visual acuitybusiness.industry05 social sciencesHealthy subjectsmedicine.disease960Ophthalmologymedicine.anatomical_structurelcsh:RE1-994030221 ophthalmology & optometryOptometryHuman eyeAccommodative lagbusinessAccommodationInternational Journal of Ophthalmology
researchProduct